The concept of treatment-free remission in chronic myeloid leukemia

por Saußele, S, Richter, J, Hochhaus, A, Mahon, F-X
Publicado 2016

PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor

por Airiau, K, Mahon, F-X, Josselin, M, Jeanneteau, M, Belloc, F
Publicado 2013

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells

por Joha, S, Nugues, A-L, Hétuin, D, Berthon, C, Dezitter, X, Dauphin, V, Mahon, F-X, Roche-Lestienne, C, Preudhomme, C, Quesnel, B, Idziorek, T
Publicado 2012

Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence

por Drullion, C, Trégoat, C, Lagarde, V, Tan, S, Gioia, R, Priault, M, Djavaheri-Mergny, M, Brisson, A, Auberger, P, Mahon, F-X, Pasquet, J-M
Publicado 2012

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

por le Coutre, P D, Hughes, T P, Mahon, F-X, Kim, D-W, Steegmann, J L, Shah, N P, Gooden, K, Wallis, N, Cortes, J E
Publicado 2016

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

por Seymour, J F, Kim, D W, Rubin, E, Haregewoin, A, Clark, J, Watson, P, Hughes, T, Dufva, I, Jimenez, J L, Mahon, F-X, Rousselot, P, Cortes, J, Martinelli, G, Papayannidis, C, Nagler, A, Giles, F J
Publicado 2014

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

por Hughes, T P, Leber, B, Cervantes, F, Spector, N, Pasquini, R, Clementino, N C D, Schwarer, A P, Dorlhiac-Llacer, P E, Mahon, F-X, Rea, D, Guerci-Bresler, A, Kamel-Reid, S, Bendit, I, Acharya, S, Glynos, T, Dalal, D, Branford, S, Lipton, J H
Publicado 2017

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

por Hochhaus, A, Rosti, G, Cross, N C P, Steegmann, J L, le Coutre, P, Ossenkoppele, G, Petrov, L, Masszi, T, Hellmann, A, Griskevicius, L, Wiktor-Jedrzejczak, W, Rea, D, Coriu, D, Brümmendorf, T H, Porkka, K, Saglio, G, Gastl, G, Müller, M C, Schuld, P, Di Matteo, P, Pellegrino, A, Dezzani, L, Mahon, F-X, Baccarani, M, Giles, F J
Publicado 2016

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

por Ilander, M, Olsson-Strömberg, U, Schlums, H, Guilhot, J, Brück, O, Lähteenmäki, H, Kasanen, T, Koskenvesa, P, Söderlund, S, Höglund, M, Markevärn, B, Själander, A, Lotfi, K, Dreimane, A, Lübking, A, Holm, E, Björeman, M, Lehmann, S, Stenke, L, Ohm, L, Gedde-Dahl, T, Majeed, W, Ehrencrona, H, Koskela, S, Saussele, S, Mahon, F-X, Porkka, K, Hjorth-Hansen, H, Bryceson, Y T, Richter, J, Mustjoki, S
Publicado 2017

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

por Blay, J.Y., Boucher, S., Le Vu, B., Cropet, C., Chabaud, S., Perol, D., Barranger, E., Campone, M., Conroy, T., Coutant, C., De Crevoisier, R., Debreuve-Theresette, A., Delord, J.P., Fumoleau, P., Gentil, J., Gomez, F., Guerin, O., Jaffré, A., Lartigau, E., Lemoine, C., Mahe, M.A., Mahon, F.X., Mathieu-Daude, H., Merrouche, Y., Penault-Llorca, F., Pivot, X., Soria, J.C., Thomas, G., Vera, P., Vermeulin, T., Viens, P., Ychou, M., Beaupere, S.
Publicado 2021

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

por Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F., Niederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saußele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A., Hehlmann, R.
Publicado 2020

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

por Cross, N C P, White, H E, Ernst, T, Welden, L, Dietz, C, Saglio, G, Mahon, F-X, Wong, C C, Zheng, D, Wong, S, Wang, S-S, Akiki, S, Albano, F, Andrikovics, H, Anwar, J, Balatzenko, G, Bendit, I, Beveridge, J, Boeckx, N, Cerveira, N, Cheng, S-M, Colomer, D, Czurda, S, Daraio, F, Dulucq, S, Eggen, L, El Housni, H, Gerrard, G, Gniot, M, Izzo, B, Jacquin, D, Janssen, J J W M, Jeromin, S, Jurcek, T, Kim, D-W, Machova-Polakova, K, Martinez-Lopez, J, McBean, M, Mesanovic, S, Mitterbauer-Hohendanner, G, Mobtaker, H, Mozziconacci, M-J, Pajič, T, Pallisgaard, N, Panagiotidis, P, Press, R D, Qin, Y-Z, Radich, J, Sacha, T, Touloumenidou, T, Waits, P, Wilkinson, E, Zadro, R, Müller, M C, Hochhaus, A, Branford, S
Publicado 2016